Superficial mucoceles as a sequel to Stevens‑Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature

Chwiałkowska,Vasiliki; Słowińska,Monika; Płatkowska,Anna; Kania,Joanna; Parciak,Karolina; Czarnecka,Anna; Teterycz,Paweł; Owczarek,Witold

doi:10.3892/etm.2024.12765

Superficial mucoceles as a sequel to Stevens‑Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature

Authors:
- Vasiliki Chwiałkowska
- Monika Słowińska
- Anna Płatkowska
- Joanna Kania
- Karolina Parciak
- Anna Czarnecka
- Paweł Teterycz
- Witold Owczarek
View Affiliations

Affiliations: Department of Dermatology, Military Institute of Medicine‑National Research Institute, Central Clinical Hospital Ministry of Defense, 04‑141 Warsaw, Poland, Department of Pathomorphology, Military Institute of Medicine‑National Research Institute, Central Clinical Hospital Ministry of Defense, 04‑141 Warsaw, Poland, Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska‑Curie National Research Institute of Oncology, 02‑781 Warsaw, Poland
Published online on: November 18, 2024 https://doi.org/10.3892/etm.2024.12765
Article Number: 15
Copyright: © Chwiałkowska et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Superficial mucoceles (SM) are small, benign, translucent vesicles, which develop in the oral mucosa, mainly on the lower lip, due to a rupture of minor salivary gland ducts and the extravasation of saliva. The use of immune checkpoint blockade treatment may lead to dermatologic immune‑related adverse events in 40‑50% of patients and with severe dermatologic immune adverse events of Common Terminology Criteria for Adverse Events of grade G3‑G4 in 1‑2% of patients. The present study described the case of a patient with squamous cell carcinoma treated with cemiplimab with the adverse effect of Stevens‑Johnson syndrome. The patient developed multiple SM, which made it challenging for the patient to speak and eat. Ablative treatment using a plasma device (Plasma IQ) and electrocoagulation were used to remove all lesions, which achieved a precise and timely therapeutic effect without any remainder of scarring. Through the publication of the present case report and literature review, the present article aimed to enhance the understanding of this condition, providing valuable diagnostic and therapeutic information about the spectrum of mucosal involvement among drug‑related toxicities of current oncological treatment.

View Figures

View References

1	Pandarathodiyil AK and Sivapathasundharam B: Diagnostic challenges of superficial mucoceles: An update. J Oral Maxillofac Pathol. 27:616–621. 2023.PubMed/NCBI View Article : Google Scholar
2	Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, et al: Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. Cancers (Basel). 13(3547)2021.PubMed/NCBI View Article : Google Scholar
3	Bray ER, Lin RR, Li JN, Elgart GW, Elman SA and Maderal AD: Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: A review of 98 cases. Arch Dermatol Res. 316(233)2024.PubMed/NCBI View Article : Google Scholar
4	Lin M, Gong T, Ruan S, Lv X, Chen R, Su X, Cheng B and Ji C: Emerging insights into stevens-johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy. J Inflamm Res. 17:2337–2351. 2024.PubMed/NCBI View Article : Google Scholar
5	Amy DPB, Shalabi A, Finfter O, Birenzweig Y and Zadik Y: Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: New cases and a review of the literature. Immunotherapy. 12:777–784. 2020.PubMed/NCBI View Article : Google Scholar
6	Elad S, Yarom N, Zadik Y, Kuten-Shorrer M and Sonis ST: The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 72:57–77. 2022.PubMed/NCBI View Article : Google Scholar
7	Srivastava A, Nogueras-Gonzalez GM, Geng Y, Singh J, Myers JN, Li Y and Chambers MS: Oral toxicities associated with immune checkpoint inhibitors: Meta-analyses of clinical trials. J Immunother Precis Oncol. 7:24–40. 2024.PubMed/NCBI View Article : Google Scholar
8	Heguedusch D, Tomo S, Almeida OP and Alves FA: Superficial mucoceles in cancer patients: A retrospective series from a Stomatology unit. Med Oral Patol Oral Cir Bucal. 28:e562–e566. 2023.PubMed/NCBI View Article : Google Scholar
9	Salati M, Pifferi M, Baldessari C, Bertolini F, Tomasello C, Cascinu S and Barbieri F: Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 29:283–284. 2018.PubMed/NCBI View Article : Google Scholar
10	Gracia-Cazaña T, Padgett E, Calderero V and Oncins R: Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer. Dermatol Online J. 27(13030/qt2897t6dq)2021.PubMed/NCBI
11	Pîrlog CF, Paroșanu AI, Slavu CO, Olaru M, Popa AM, Iaciu C, Niță I, Moțatu P, Horia C, Manolescu LSC and Nițipir C: Nivolumab hypersensitivity reactions a Myth or reality in solid tumors-a systematic review of the literature. Curr Oncol. 29:9428–9436. 2022.PubMed/NCBI View Article : Google Scholar
12	Shah KM, Rancour EA, Al-Omari A and Rahnama-Moghadam S: Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J. 24(13030/qt97g3t63v)2018.PubMed/NCBI
13	Dasanu CA: Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol Pharm Pract. 25:2052–2055. 2019.PubMed/NCBI View Article : Google Scholar
14	Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y and Tomii K: Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 109:58–61. 2017.PubMed/NCBI View Article : Google Scholar
15	Chirasuthat P and Chayavichitsilp P: Atezolizumab-Induced stevens-johnson syndrome in a patient with non-small cell lung carcinoma. Case Rep Dermatol. 10:198–202. 2018.PubMed/NCBI View Article : Google Scholar
16	Hammond S, Olsson-Brown A, Gardner J, Thomson P, Ali SE, Jolly C, Carr D, Ressel L, Pirmohamed M and Naisbitt D: T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. J Immunother Cancer. 9(e002521)2021.PubMed/NCBI View Article : Google Scholar
17	Saw S, Lee HY and Ng QS: Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 81:237–239. 2017.PubMed/NCBI View Article : Google Scholar
18	Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, et al: Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 5(e1214788)2016.PubMed/NCBI View Article : Google Scholar
19	Sandhu M, Kc B, Bhandari J, Gambhir HS and Farah R: Pembrolizumab-associated stevens-johnson syndrome in a patient with metastatic non-small cell lung cancer: A case report. Cureus. 15(e41439)2023.PubMed/NCBI View Article : Google Scholar
20	Riano I, Cristancho C and Treadwell T: Stevens-Johnson syndrome-like reaction after exposure to pembrolizumab and recombinant zoster vaccine in a patient with metastatic lung cancer. J Investig Med High Impact Case Rep. 8(2324709620914796)2020.PubMed/NCBI View Article : Google Scholar
21	Machida M, Yamazaki C, Kouda N, Hanai Y, Sato H, Konda A, Yamagata Y, Itho T and Aisaka H: A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer. J Pharm Health Care Sci. 8(29)2022.PubMed/NCBI View Article : Google Scholar
22	Wu JY, Kang K, Yi J and Yang B: Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. World J Clin Cases. 10:6110–6118. 2022.PubMed/NCBI View Article : Google Scholar
23	Lopez M, Hagopian G, Doan L, Lee BJ, Rojek NW, Smith J, Ou SI, Demirdag YY and Nagasaka M: Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab. Allergy Asthma Clin Immunol. 19(93)2023.PubMed/NCBI View Article : Google Scholar
24	Haratake N, Tagawa T, Hirai F, Toyokawa G, Miyazaki R and Maehara Y: Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient. J Thorac Oncol. 13:1798–1799. 2018.PubMed/NCBI View Article : Google Scholar
25	Gianni C, Bronte G, Delmonte A, Burgio MA, Andrikou K, Monti M, Menna C, Frassineti GL and Crinò L: Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma. Front Pharmacol. 12(672233)2021.PubMed/NCBI View Article : Google Scholar
26	Godfrey H, Jedlowski P and Thiede R: Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System. Australas J Dermatol. 65:243–253. 2024.PubMed/NCBI View Article : Google Scholar
27	Hwang A, Iskandar A and Dasanu CA: Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract. 25:1520–1522. 2019.PubMed/NCBI View Article : Google Scholar
28	Zhang J, Zhang P, Xu QY, Zhu YT, Chen W and Ji C: Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma. Australas J Dermatol. 63:e71–e74. 2022.PubMed/NCBI View Article : Google Scholar
29	Kamei J, Yokoyama H, Niki T, Suda R, Sugihara T, Fujisaki A, Ando S, Iwami D and Fujimura T: Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney. IJU Case Rep. 5:199–202. 2022.PubMed/NCBI View Article : Google Scholar
30	Li X, Lei Y, Liu J, Lin H, Chen K, Yin F, Wang C and Zhang H: Case report: A successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies. Discov Oncol. 14(146)2023.PubMed/NCBI View Article : Google Scholar
31	Dika E, Ravaioli GM, Fanti PA, Piraccini BM, Lambertini M, Chessa MA, Baraldi C, Ribero S, Andrea A, Melotti B and Patrizi A: Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: A prospective study. Eur J Dermatol. 27:266–270. 2017.PubMed/NCBI View Article : Google Scholar
32	Alexandris D, Alevizopoulos N, Gakiopoulou H, Stavrinou N and Vourlakou C: Cutaneous Stevens Johnson-Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients. J Oncol Pharm Pract. 28:1276–1282. 2022.PubMed/NCBI View Article : Google Scholar
33	Rouyer L, Bursztejn AC, Charbit L, Schmutz JL and Moawad S: Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. Eur J Dermatol. 28:380–381. 2018.PubMed/NCBI View Article : Google Scholar
34	Ryu S, Jun I, Kim TI, Seo KY and Kim EK: Pembrolizumab-induced stevens-johnson syndrome with severe ocular complications. Ocul Immunol Inflamm. 30:1533–1535. 2022.PubMed/NCBI View Article : Google Scholar
35	Rodríguez-Otero N, Chamorro-Pérez J, Fernández-Lozano C, Elías-Sáenz I, Berná-Rico E, de Nicolás-Ruanes B, Meléndez-Gispert MR, Moreno-García Del Real C, Martínez-Botas J, Cortés-Salgado A and Solano-Solares E: Nivolumab-induced Stevens-Johnson syndrome: not only due to PD-1 inhibition. J Allergy Clin Immnol Pract. 11:2936–2938.e1. 2023.PubMed/NCBI View Article : Google Scholar
36	Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE and Dummer R: Cytotoxic cutaneous adverse drug reactions during Anti-PD-1 therapy. Clin Cancer Res. 22:4023–4029. 2016.PubMed/NCBI View Article : Google Scholar
37	Pierre AB, Jernigan AM and Castellano T: SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color. Gynecol Oncol Rep. 50(101290)2023.PubMed/NCBI View Article : Google Scholar
38	Robinson S, Saleh J, Curry J and Mudaliar K: Pembrolizumab-Induced stevens-johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: A case report. Am J Dermatopathol. 42:292–296. 2020.PubMed/NCBI View Article : Google Scholar
39	Saad E, Adhikari P, Antala D, Abdulrahman A, Begiashvili V, Mohamed K, Ali E and Zhang Q: Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma. J Med Cases. 13:449–455. 2022.PubMed/NCBI View Article : Google Scholar
40	Cao J, Li Q, Zhi X, Yang F, Zhu W, Zhou T, Hou X and Chen D: Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: A case report. Transl Cancer Res. 10:3870–3876. 2021.PubMed/NCBI View Article : Google Scholar
41	Oguri T, Sasada S, Shimizu S, Shigematsu R, Tsuchiya Y, Ishioka K, Takahashi S, Oki K, Kimura Y, Seki R, et al: A case of guillain-barré syndrome and stevens-johnson syndrome/toxic epidermal necrosis overlap after pembrolizumab treatment. J Investig Med High Impact Case Rep. 9(23247096211037462)2021.PubMed/NCBI View Article : Google Scholar
42	Maloney NJ, Ravi V, Cheng K, Bach DQ and Worswick S: Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review. Int J Dermatol. 59:e183–e188. 2020.PubMed/NCBI View Article : Google Scholar
43	Nayar N, Briscoe K and Fernandez Penas P: Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother. 39:149–152. 2016.PubMed/NCBI View Article : Google Scholar
44	Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA and Seminario-Vidal L: Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 44:381–384. 2017.PubMed/NCBI View Article : Google Scholar
45	Koshizuka K, Sakurai D, Sunagane M, Mita Y, Hamasaki S, Suzuki T, Kikkawa N, Nakano M and Hanazawa T: Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer. Clin Case Rep. 9:848–852. 2020.PubMed/NCBI View Article : Google Scholar
46	Pintea I, Petricau C, Dumitrascu D, Muntean A, Branisteanu DC, Branisteanu DE and Deleanu D: Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review). Exp Ther Med. 22(949)2021.PubMed/NCBI View Article : Google Scholar
47	Basu P, Tong Y, Hinds BR and Schneider JA: Nivolumab-induced toxic epidermal necrolysis with retiform purpura. Br J Dermatol. 183(e32)2020.PubMed/NCBI View Article : Google Scholar
48	Keerty D, Koverzhenko V, Belinc D, LaPorta K and Haynes E: Immune-Mediated toxic epidermal necrolysis. Cureus. 12(e9587)2020.PubMed/NCBI View Article : Google Scholar
49	Kim MC and Khan HN: Nivolumab-Induced toxic epidermal necrolysis: Rare but fatal complication of immune checkpoint inhibitor therapy. Cureus. 13(e15017)2021.PubMed/NCBI View Article : Google Scholar
50	Griffin LL, Cove-Smith L, Alachkar H, Radford JA, Brooke R and Linton KM: Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Rep. 4:229–231. 2018.PubMed/NCBI View Article : Google Scholar
51	Gopee NH, Gourley AM, Oliphant TJ and Hampton PJ: Toxic epidermal necrolysis occurring with immune checkpoint inhibitors. Dermatol Online J. 26(13030/qt8fc428f6)2020.PubMed/NCBI
52	Gallo Marin B, Oliva R, Kahn B, Borgovan T, Brooks BE and Massoud CM: Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma. R I Med J (2013). 105:34–36. 2022.PubMed/NCBI
53	Neema S, Sathu S, Vasudevan B, Shreshta S, Bhatt S and K L: Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction. Indian J Dermatol Venereol Leprol. 89:589–591. 2023.PubMed/NCBI View Article : Google Scholar
54	Kian W, Zemel M, Elobra F, Sharb AA, Levitas D, Assabag Y, Alguayn F, Yakobson A, Rouvinov K and Fuchs L: Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 33:e738–e740. 2022.PubMed/NCBI View Article : Google Scholar
55	Eldani C, Darrigade AS, Beylot-Barry M, Jullie ML, Ducharme O, Milpied B and Pham-Ledard A: Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as ‘toxic epidermal necrolysis-like’. Eur J Dermatol. 32:805–807. 2022.PubMed/NCBI View Article : Google Scholar
56	Borg L, Buhagiar M, La Ferla E, Pisani D, Said J and Boffa MJ: Pembrolizumab-Induced Toxic Epidermal Necrolysis. Case Rep Oncol. 15:887–893. 2022.PubMed/NCBI View Article : Google Scholar
57	Chow KVC, O'Leary C, Paxton-Hall F, Lambie D and O'Byrne K: Pembrolizumab-induced toxic epidermal necrolysis: Case report. Oxf Med Case Reports. 2022(omac025)2022.PubMed/NCBI View Article : Google Scholar
58	Cai ZR, Lecours J, Adam JP, Marcil I, Blais N, Dallaire M, Belisle A and Mathieu A: Toxic epidermal necrolysis associated with pembrolizumab. J Oncol Pharm Pract. 26:1259–1265. 2020.PubMed/NCBI View Article : Google Scholar
59	Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
60	US Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health, National Cancer Institute, 2017.
61	Yang A, Xuan R, Melbourne W, Tran K and Murrell DF: Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. J Eur Acad Dermatol Venereol. 34:153–160. 2020.PubMed/NCBI View Article : Google Scholar
62	Ellis SR, Vierra AT, Millsop JW, Lacouture ME and Kiuru M: Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol. 83:1130–1143. 2020.PubMed/NCBI View Article : Google Scholar
63	Teng YS and Yu S: Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol. 30:6805–6819. 2023.PubMed/NCBI View Article : Google Scholar
64	Reike MJ, Bahlburg H, Brehmer M, Berg S, Noldus J, Roghmann F, Bach P and Tully KH: Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer. Cancer Epidemiol. 90(102574)2024.PubMed/NCBI View Article : Google Scholar
65	Lacouture ME, Patel AB, Rosenberg JE and O'Donnell PH: Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. 27:e223–e232. 2022.PubMed/NCBI View Article : Google Scholar
66	Xia C, Jiang C, Li W, Wei J, Hong H, Li J, Feng L, Wei H, Xin H and Chen T: A phase II Randomized clinical trial and mechanistic studies using improved probiotics to prevent oral mucositis induced by concurrent radiotherapy and chemotherapy in nasopharyngeal carcinoma. Front Immunol. 12(618150)2021.PubMed/NCBI View Article : Google Scholar
67	Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A and Strano S: Oral mucositis: The hidden side of cancer therapy. J Exp Clin Cancer Res. 39(210)2020.PubMed/NCBI View Article : Google Scholar
68	Maria OM, Eliopoulos N and Muanza T: Radiation-Induced oral mucositis. Front Oncol. 7(89)2017.PubMed/NCBI View Article : Google Scholar
69	Radochová V, Šembera M, Slezák R, Heneberk O and Radocha J: Oral Mucositis association with periodontal status: A retrospective analysis of 496 patients undergoing hematopoietic stem cell transplantation. J Clin Med. 10(5790)2021.PubMed/NCBI View Article : Google Scholar
70	Lacouture M and Sibaud V: Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 19 (Suppl 1):S31–S39. 2018.PubMed/NCBI View Article : Google Scholar
71	Vigarios E, Epstein JB and Sibaud V: Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 25:1713–1739. 2017.PubMed/NCBI View Article : Google Scholar
72	Klein BA, Alves FA, de Santana Rodrigues Velho J, Vacharotayangul P, Hanna GJ, LeBoeuf NR, Shazib MA, Villa A, Woo SB, Sroussi H, et al: Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Oral Dis. 28:9–22. 2022.PubMed/NCBI View Article : Google Scholar
73	Lloyd-Lavery A, Hodgson T, Coupe N, Bond S, Shah K, Espinosa O, Payne MJ, Middleton MR and Matin RN: Delayed oral toxicity from long-term vemurafenib therapy. Br J Dermatol. 174:1159–1160. 2016.PubMed/NCBI View Article : Google Scholar
74	Shephard MK and Lloyd-Lavery A: Resolution of severe oral mucosal changes related to vemurafenib therapy with intensive periodontal treatment. Br J Dermatol. 181:639–640. 2019.PubMed/NCBI View Article : Google Scholar
75	Pileri A, Cricca M, Gandolfi L, Misciali C, Casadei B, Zinzani PL and Patrizi A: Vemurafenib mucosal side-effect. J Eur Acad Dermatol Venereol. 30:1053–1055. 2016.PubMed/NCBI View Article : Google Scholar
76	Prado-Ribeiro AC, Santos-Silva AR, Faria KM, Silva WG, Simonato LE, Moutinho K and Brandão TB: Radiation-related superficial oral mucoceles: An under-recognized acute toxicity in head and neck cancer patients. Med Oral Patol Oral Cir Bucal. 23:e518–e523. 2018.PubMed/NCBI View Article : Google Scholar
77	Campana F, Sibaud V, Chauvel A, Boiron JM, Taieb A and Fricain JC: Recurrent superficial mucoceles associated with lichenoid disorders. J Oral Maxillofac Surg. 64:1830–1833. 2006.PubMed/NCBI View Article : Google Scholar
78	Demarosi F, Lodi G, Carrassi A and Sardella A: Superficial oral mucoceles: Description of two cases in patients with graft-versus-host disease. J Otolaryngol. 36:E76–E78. 2007.PubMed/NCBI
79	Balasubramaniam R, Alawi F and DeRossi S: Superficial mucoceles in chronic graft-versus-host disease: A case report and review of the literature. Gen Dent. 57:82–88. 2009.PubMed/NCBI
80	García-F-Villalta MJ, Pascual-López M, Elices M, Daudén E, García-Diez A and Fraga J: Superficial mucoceles and lichenoid graft versus host disease: report of three cases. Acta Derm Venereol. 82:453–455. 2002.PubMed/NCBI View Article : Google Scholar
81	Brooks JK, Schwartz KG and Basile JR: Superficial mucocele of the ventral tongue: Presentation of a rare case and literature review. J Oral Maxillofac Surg. 74:1175–1179. 2016.PubMed/NCBI View Article : Google Scholar
82	Masri BA, Perry LM and Stoopler ET: Palatal superficial mucoceles associated with chronic graft-versus-host disease. Hematol Transfus Cell Ther. 45(140)2023.PubMed/NCBI View Article : Google Scholar
83	Deutsch A and McLellan BN: Topical tacrolimus for refractory superficial mucoceles in a patient with chronic graft versus host disease. JAAD Case Rep. 6:426–427. 2020.PubMed/NCBI View Article : Google Scholar
84	Nicolatou-Galitis O, Kitra V, Van Vliet-Constantinidou C, Peristeri J, Goussetis E, Petropoulos D and Grafakos S: The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med. 30:148–153. 2001.PubMed/NCBI View Article : Google Scholar
85	Zadik Y, Keshet N and Aframian DJ: Oral superficial mucocele in cancer patients. Oral Oncol. 56:e15–e16. 2016.PubMed/NCBI View Article : Google Scholar
86	Pengpis N, Prueksrisakul T and Chanswangphuwana C: Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria. Med Oral Patol Oral Cir Bucal. 28:e167–e173. 2023.PubMed/NCBI View Article : Google Scholar
87	Elad S, Zadik Y and Yarom N: Oral complications of nonsurgical cancer therapies. Atlas Oral Maxillofac Surg. Clin. North Am. 25:133–147. 2017.PubMed/NCBI View Article : Google Scholar
88	Eveson JW: Superficial mucoceles: Pitfall in clinical and microscopic diagnosis. Oral Surg Oral Med Oral Pathol. 66:318–322. 1988.PubMed/NCBI View Article : Google Scholar
89	Rather S, Shah AA, Shah FY, Kaur S, Bhat MA, Reyaz S and Hassan I: Dermoscopy of oral mucosal lesions: experience from a tertiary care center in north india and review of literature. Indian Dermatol Online J. 13:346–360. 2022.PubMed/NCBI View Article : Google Scholar
90	Ayhan E, Toprak SF, Kaya Ş and Akkaynak Ş: Dermoscopy of oral mucocele: Three types of extravasation mucoceles. Turk J Med Sci. 50:96–102. 2020.PubMed/NCBI View Article : Google Scholar
91	Kumar Jha A, Vinay K, Sławińska M, Sonthalia S, Sobjanek M, Kamińska-Winciorek G, Errichetti E, Kamat D, Chatterjee D, Apalla Z, et al: Application of mucous membrane dermoscopy (mucoscopy) in diagnostics of benign oral lesions-literature review and preliminary observations from International Dermoscopy Society study. Dermatol Ther. 34(e14478)2021.PubMed/NCBI View Article : Google Scholar
92	Manfredini M, Pedroni G, Bigi L, Apponi R, Murri Dello Diago A, Dattola A, Farnetani F and Pellacani G: Acquired white oral lesions with specific patterns: Oral lichen planus and lupus erythematosus. Dermatol Pract Concept. 11(e2021074)2021.PubMed/NCBI View Article : Google Scholar
93	Venugopal DC, Warrier SA, S E, H T and Ramesh P: Superficial Mucocele: A Rare Presentation. Cureus. 13(e18038)2021.PubMed/NCBI View Article : Google Scholar
94	Płatkowska A, Słowińska M, Zalewska J, Swacha Z, Szumera-Ciećkiewicz A, Wągrodzki M, Patera J, Łapieńska-Rey K, Lorent M, Ługowska I, et al: Minimally Invasive plasma device management of multiple benign skin cancers associated with rare genodermatoses-case series and review of the therapeutic methods. J Clin Med. 13(4377)2024.PubMed/NCBI View Article : Google Scholar
95	Holcomb JD, Kalhan R and Pilcher B: Evaluation of skin tissue effects from treatment with a novel hand-held plasma energy device. J Cosmet Dermatol. 21:1998–2004. 2022.PubMed/NCBI View Article : Google Scholar
96	Bell A and Kasi A: Oral Mucositis. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2024.
97	National Library of Medicine: Stomatitides. https://www.ncbi.nlm.nih.gov/medgen/52511.
98	Lee JH, Lee JH, Lee JH, Kim SY and Kim GM: Case of sunitinib-induced Stevens-Johnson syndrome. J Dermatol. 40:753–754. 2013.PubMed/NCBI View Article : Google Scholar
99	Gronich N, Maman D, Stein N and Saliba W: Culprit medications and risk factors associated with stevens-johnson syndrome and toxic epidermal necrolysis: Population-Based nested case-control study. Am J Clin Dermatol. 23:257–266. 2022.PubMed/NCBI View Article : Google Scholar
100	Vinay K, Yanamandra U, Dogra S, Handa S, Suri V, Kumari S, Khadwal A, Prakash G, Lad D, Varma S and Malhotra P: Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. Int J Dermatol. 57:332–338. 2018.PubMed/NCBI View Article : Google Scholar
101	Yang S, Wu L, Li X, Huang J, Zhong J and Chen X: Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient. Mol Clin Oncol. 8:457–459. 2018.PubMed/NCBI View Article : Google Scholar
102	Koizumi T, Fukushima T, Tatai T, Kobayashi T, Sekiguchi N, Sakamoto A and Sasaki S: Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer. Lung Cancer. 88:112–113. 2015.PubMed/NCBI View Article : Google Scholar
103	European Medicines Agency: ANNEX I: Summary of product characteristics: MabThera. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf.
104	Patrizi A, Venturi M, Dika E, Maibach H, Tacchetti P and Brandi G: Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: New drugs, old side effects. Cutan Ocul Toxicol. 33:1–6. 2014.PubMed/NCBI View Article : Google Scholar
105	European Medicines Agency: ANNEX I: Summary of product characteristics: velcade. https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf.
106	Villa A and Kuten-Shorrer M: Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy. Int J Mol Sci. 24(8188)2023.PubMed/NCBI View Article : Google Scholar
107	Kurian CJ, Desai A, Rafferty W and Abou Hussein AK: Case report: Alpelisib-induced Stevens-Johnson syndrome. Front Oncol. 12(954027)2022.PubMed/NCBI View Article : Google Scholar
108	Nunnery SE and Mayer IA: Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 30 (Suppl_10):x21–x26. 2019.PubMed/NCBI View Article : Google Scholar
109	European Medicines Agency: ANNEX I: Summary of product characteristics: Piqray. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf.
110	Vigarios E, Beylot-Barry M, Jegou MH, Oberic L, Ysebaert L and Sibaud V: Dose-limiting stomatitis associated with ibrutinib therapy: A case series. Br J Haematol. 185:784–788. 2019.PubMed/NCBI View Article : Google Scholar
111	European Medicines Agency: ANNEX I: Summary of product characteristics: imbruvica. https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf.
112	European Medicines Agency: ANNEX I: Summary of product characteristics: venclyxto. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf.